Conflicts of interest W.H.I.M. has filed patents relating to genetic testing and therapy development aimed at the filaggrin gene.
FLG mutation p.Lys4021X in the C-terminal imperfect filaggrin repeat in Japanese patients with atopic eczema
Article first published online: 7 AUG 2009
© 2009 The Authors. Journal Compilation © 2009 British Association of Dermatologists
British Journal of Dermatology
Volume 161, Issue 6, pages 1387–1390, December 2009
How to Cite
Nemoto-Hasebe, I., Akiyama, M., Nomura, T., Sandilands, A., McLean, W.H.I. and Shimizu, H. (2009), FLG mutation p.Lys4021X in the C-terminal imperfect filaggrin repeat in Japanese patients with atopic eczema. British Journal of Dermatology, 161: 1387–1390. doi: 10.1111/j.1365-2133.2009.09406.x
- Issue published online: 17 NOV 2009
- Article first published online: 7 AUG 2009
- Accepted for publication 4 June 2009
Options for accessing this content:
- If you are a society or association member and require assistance with obtaining online access instructions please contact our Journal Customer Services team.
- If your institution does not currently subscribe to this content, please recommend the title to your librarian.
- Login via other institutional login options http://onlinelibrary.wiley.com/login-options.
- You can purchase online access to this Article for a 24-hour period (price varies by title)
- If you already have a Wiley Online Library or Wiley InterScience user account: login above and proceed to purchase the article.
- New Users: Please register, then proceed to purchase the article.
Login via OpenAthens
Search for your institution's name below to login via Shibboleth.
Registered Users please login:
- Access your saved publications, articles and searches
- Manage your email alerts, orders and subscriptions
- Change your contact information, including your password
Please register to:
- Save publications, articles and searches
- Get email alerts
- Get all the benefits mentioned below!
Patients and/or caregivers may access this content for use in relation to their own personal healthcare or that of a family member only. Terms and conditions will apply.